Sedation – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 46
Inquire Before Buying

Sedation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Sedation – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Sedation – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sedation.
- A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sedation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sedation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Sedation – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sedation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Sedation 7
Sedation Therapeutics under Development by Companies 9
Sedation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Sedation Therapeutics - Products under Development by Companies 14
Sedation Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Sedation Therapeutics Development 16
AstraZeneca PLC 16
AcelRx Pharmaceuticals, Inc. 17
PAION AG 18
Mayne Pharma Limited 19
Sedation - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
CNS-7056 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
sufentanil + triazolam - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
zolpidem - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
propofol - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexmedetomidine hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Midazolam - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PF0713 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
flumazenil - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39
Sedation - Product Development Milestones 40
Featured News & Press Releases 40
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 40
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 40
Jul 22, 2011: Orion Receives Positive CHMP Opinion For Dexdor 41
May 18, 2011: AcelRx Pharma Presents ARX-03 Clinical Study Results At 30th Annual Scientific Meeting Of American Pain Society 41
Nov 04, 2009: Paion Reports Positive Results Of Its Short Acting Anaesthetic/Sedative CNS 7056 In A Phase IIa Study In Upper GI Endoscopy 42
Apr 20, 2009: Paion Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy 43
Nov 19, 2008: Paion Announces Successful Completion Of Phase I Study With The Sedative/Anaesthetic CNS 7056 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
AstraZeneca PLC, H2 2012 16
AcelRx Pharmaceuticals, Inc., H2 2012 17
PAION AG, H2 2012 18
Mayne Pharma Limited, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Sedation Therapeutics - Drug Profile Updates 36
Sedation Therapeutics - Discontinued Products 38
Sedation Therapeutics - Dormant Products 39

List of Figures
Number of Products under Development for Sedation, H2 2012 7
Products under Development for Sedation - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

  • Chinese Vacuum Pumps Industry to Grow at a CAGR of 5.5% to 2018
    A vacuum pump is used in most of the activities we do in our every day life. Some of its regular application are air conditioning, automobiles, CDs andDVDs, television tubes, etc. It is also used in hi-tech companies for creating process like coating of microchips and also manufacturing of optical glass or analytical instruments. The [...]
  • Overcoming Obesity
    In today’s world where there are countries struggling to overcome famine and shortage of food there are others who are increasingly getting populated with obese people. Obesity is one of the key problem many are facing across the world. It is a result of either improper lifestyle and food habits or is completely hereditary. In [...]
  • The Booming Market of Carbon Fibre
    The speed at which the Carbon Fibre Industry is growing it is sure to be one of the most profitable industry in the years to come. The sales of carbon fibre tow is expected to increase from $1.6 billion in 2011 to $4.5 billion in 2020. The overall The global demand for carbon fibre tow [...]
  • Incentivising Research & Development Activities
    Research and Development (R&D) is the base of innovation, competitiveness and economic performance. Any company or a country that seeks to be ahead of its competitors need to invest heavily in setting up an active R&D wing. In today’s world everything is technology oriented.  People are coming up with new ideas, products and newer ways [...]
  • Global Cystic Fibrosis Market Propelled by Technological Advancement
    With increasing prevalence of cystic fibrosis and its growing awareness among people, the global market for cystic fibrosis is expected to grow at a steady pace. Cystic fibrosis is a genetic condition where the lungs and digestive system becomes clogged with excess mucus. This condition is more common among Caucasian population than people of Asian [...]
  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Retaining the Hard-Won Consumers
  • With the increase in mobile phone usage different operators are coming up with different plan in order to cater to users of all age-group with various data plan to choose from. With the maturing mobile market operators are coming up …

  • To bring in Photography to the Real World Visual Supply Co Acquires Artifact Uprising
  • Visual Supply Co, VSCO has brought a Denver-based startup, Artifact Uprising, which is focused on bringing photographers’ work from the digital hubs on regular basis by modern creatives to the real world as prints and tangible books. Artifact Uprising is …

  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Slovenia Medical Devices Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 129
    BMI Industry View: The Slovenian medical device market is expected to grow by just 0.6% per annum to 2018, but a struggling economy and political instability, not to mention allegations of corruption and division within the healthcare system, could further affect funding and spending patterns in the short to medium term. Headline Industry Forecasts ? The medical equipment market is small, constrained by the country's small size. It is, however, one of the richest markets in the European region w......
  • Botswana Pharmaceuticals and Healthcare Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 66
    BMI View: With Botswana's plans to manufacture drugs locally stalling, the country will remain reliant on importing its pharmaceutical needs for the foreseeable future. The government's commitment to healthcare sector development will continue driving import growth to outperform exports. Botswana makes an attractive manufacturing destination, though its small market size is a deterrent to investment. Headline Expenditure Projections ? Pharmaceuticals: BWP1.82bn (USD203mn) in 2014 to BWP1.99bn (U......
  • South Africa Medical Devices Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 158
    BMI Industry View: The medium term prospects for the medical device industry look encouraging; based on current trends, the market, of which over 90% is supplied by imports, is expected to grow at a CAGR of 5.6% from 2013-2018. A key driver of growth is expected to be the public-private partnerships to develop hospitals in South Africa but this could be tempered slightly, by a depreciating rand against the US dollar and the general state of the South African economy. The long term growth prospec......
  • Brazil Pharmaceuticals and Healthcare Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 144
    BMI View: Continued regulatory improvements, growing pharmaceutical and healthcare markets, and increased favour for foreign investment will allow Brazil to maintain its position as the regional outperformer in Latin America. However, low affordability and increasing generic drug competition will hamper opportunities for innovative drugmakers as the country continues to develop its economy. Headline Expenditure Projections Pharmaceuticals: BRL62.0bn (USD26.3bn) in 2014 to BRL65.3bn (USD25.6bn) i......
  • Sweden Medical Devices Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 159
    BMI Industry View: The medical device market is expected to experience moderate growth in local currency terms over the forecast period but growth in US dollar terms will be constrained by a depreciation of the Swedish krona against the US dollar. Although Sweden has a strong medical device manufacturing industry including a number of major international companies, the majority of domestically produced medical devices are exported, leaving the domestic market heavily dependent on imports. Headli......
  • China Pharmaceuticals and Healthcare Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 198
    BMI View: Pharmaceutical sales in China will continue to grow robustly - boosted by the improvement in healthcare access, liberalisation of the industry as well as an epidemiological transition towards chronic diseases. This will present strong revenue earning opportunities for both domestic and multinational pharmaceutical companies. However, downside risks to this upbeat outlook remain as the government will face pressures to contain medicine costs. Headline Expenditure Projections ? Pharmaceu......
  • Switzerland Medical Devices Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 147
    BMI Industry View: The Swiss medical device market is expected to grow by a CAGR of 1.4% over the 2013-2018 period, with other medical devices and orthopaedics & prosthetics expected to have the highest growth during this period. Over the last 15 years the Swiss medical technology sector has grown faster than almost any other sector in the country. Government technology development programmes, favourable tax rates, quality staff and research have all contributed. Headline Industry Forecasts ? In......
  • Latvia Pharmaceuticals and Healthcare Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 103
    BMI View: Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers that had sought exports to Russia and the Commonwealth of Independent States (CIS) region as a remedy for lacklustre domestic demand in recent years. Headline Expenditure Projections ? Pharmaceuticals: EUR340mn (......
  • Ukraine Medical Devices Report Q2 2015
    Published: 1-Apr-2015        Price: US $1295 Onwards        Pages: 131
    BMI Industry View: The Ukrainian medical device market is expected to grow by a CAGR of 1.5% over the 2013-2018 period, a large fall compared with previous forecasts, caused by poor economic performance that has resulted from the Ukraine crisis. Demand for expensive medical equipment is largely met by imports, although the domestic industry is gradually accounting for a larger share. Diagnostic imaging exports have increased by five times since 2005, and they accounted for over 30% of total expo......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs